Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SterisBSP:S1TE34 91 Return-on-Tangible-Equity is 66.40% as of Mar. 2026, which is 61% below its 10-year median of 170.55. GuruFocus rates BSP:S1TE34 with a GF Score™ of 91/100 and a GF Value™ of R$60.72. The stock has 1 warning sign investors should review. Among 759 Medical Devices & Instruments companies, Steris ranks better than 93.02% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Steris's annualized net income for the quarter that ended in Mar. 2026 was R$4,606 Mil. Steris's average shareholder tangible equity for the quarter that ended in Mar. 2026 was R$6,937 Mil. Therefore, Steris's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 66.40%.
The historical rank and industry rank for Steris's Return-on-Tangible-Equity or its related term are showing as below:
BSP:S1TE34'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 75.01 Med: 170.55 Max: 324.1
Current: 75.01
During the past 13 years, Steris's highest Return-on-Tangible-Equity was 324.10%. The lowest was 75.01%. And the median was 170.55%.
BSP:S1TE34's Return-on-Tangible-Equity is ranked better than 93.02% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.02
vs BSP:S1TE34: 75.01
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Steris Return-on-Tangible-Equity Related Terms
Steris Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Steris's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:S1TE34 vs ZBH, GEHC, DXCM: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Steris's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steris Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Steris's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Steris's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 66.40% mean?
Steris (BSP:S1TE34) has a Return-on-Tangible-Equity of 66.40% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Steris and its competitors. This is 61% below median its historical median of 170.55. Over the past decade, Steris' Return-on-Tangible-Equity has ranged from 75.01 to 324.10. According to the industry distribution chart, Steris ranks #53 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 7%.
Is Steris' Return-on-Tangible-Equity too high?
Steris' current Return-on-Tangible-Equity of 66.40% is 61% below median its 10-year median of 170.55. Over the past 10 years, this metric has ranged from a low of 75.01 to a high of 324.10. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.02. Steris' value of 66.40% is 1551.7% above this industry median. Based on the distribution chart, Steris ranks #53 out of 759 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Steris has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Steris' Return-on-Tangible-Equity compare to ZBH and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Steris ranks #53 out of 759 companies for Return-on-Tangible-Equity. This places Steris in the top 7% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.02. Steris' value of 66.40% is 1551.7% above this benchmark. Historically, Steris' own Return-on-Tangible-Equity has ranged from 75.01 to 324.10 over the past decade. While the company's 10-year median is 170.55 vs. the industry median of 4.02, Steris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.02, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Steris's current Return-on-Tangible-Equity of 66.40% is 1551.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Steris and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steris's current Return-on-Tangible-Equity is 66.40%, which is 61% below median its own 10-year median of 170.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Steris (BSP:S1TE34) has a current Return-on-Tangible-Equity of 66.40%. The stock's GF Value™ is R$60.72, compared to a current price of R$52.14 — trading 14.1% below its estimated fair value. The current Return-on-Tangible-Equity is 66.40%, which is 61% below median its 10-year median of 170.55 and 1551.7% above the Medical Devices & Instruments industry median of 4.02. Steris' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Steris (BSP:S1TE34), the current Return-on-Tangible-Equity is 66.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Steris (BSP:S1TE34) Overvalued in 2026?
Based on GuruFocus' analysis, Steris stock appears to be undervalued.
The current stock price of R$52.14 is trading 14.1% below its estimated GF Value™ of R$60.72.
Key valuation signals for BSP:S1TE34:
Return-on-Tangible-Equity: 66.40% (61% below median its 10-year median of 170.55)
GF Value™: R$60.72 vs. price of R$52.14 (14.1% below fair value)
Industry Position: 1551.7% above the Medical Devices & Instruments median (#53 of 759)
No single metric tells the full story. See the BSP:S1TE34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
91GF Score
Get the complete analysis for BSP:S1TE34
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:S1TE34 has been successfully added to your 
